Ex-vivo clinical candidate drug assay against field clinical isolated blood stages parasites of P. malariae and P. ovale using 10 compounds from MMV.
The main aim of this study is to develop Ex-vivo drug assay against P. ovale and P. malariae asexual blood-stage that will be used to evaluate Medicine for Malaria Venture's (MMV’s) clinical candidates' antimalarials compounds against field clinical isolated P.ovale and P.malariae.
This objective will be achieved through:
- Field collection of P. ovale and P. malariae asexual blood-stage samples in Mali and Ghana
- Development of the Ex vivo assay against P. ovale and P. malariae using reference standard antimalarial compounds obtained from MMV or Novartis and vendor
- MMV’s clinical candidate compounds evaluation against field-collected blood stage of P.ovale and P.malariae
Malaria remains one of the most important infectious diseases responsible for a high morbidity and mortality burden. Worldwide, the greatest mortality due to malaria is associated with P. falciparum infection. Plasmodium malariae (quartan fever) can result in long-lasting infection if not well treated. Plasmodium ovale and P. malariae are also believed to be responsible for asymptomatic cases (Doderer-Lang Cet al., Malar J. 2014;13:240). While most of malaria control program has instead focused on the most deadly falciparum malaria; research, drug discovery and control-elimination programs focusing on non-falciparum species such as P. ovale and P. malariae have been neglected for several decades. Since the beginning of the 21-century we have witnessed significant success in P. falciparum malaria control and for the first time, the antimalarial pipeline has several promising candidates (MMV: https://www.mmv.org/). However, the decline of P. falciparum malaria has often coincided with an increased number of the other non-falciparum species malaria cases.
Given the absence of a reliable and practical continuous cultivation system for these non-falciparum parasites that severely limiting it access for drug discovery, most of the compounds against malaria have originated from high throughput screens on the asexual blood stage of P. falciparum. Non-falciparum malaria parasite access for research and drug evaluation is thus restricted to clinical isolated samples. This is a hurdle for successful disease elimination. Effective malaria elimination programs would have to include this increasing non-falciparum species reservoir.
Longitidinal and cross-sectional study.